U.S. FDA Approves New Indication for Merck ’s Prevymis (letermovir) for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Adult Kidney Transplant Recipients

RAHWAY, N.J.--(BUSINESS WIRE) June 6, 2023 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved a new indication for Prevymis® (letermovir) for...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news